Impact of perioperative Helicobacter pylori eradication therapy on long-term survival after distal gastrectomy for gastric cancer
World Journal of Gastrointestinal Surgery · 2026-11-27 · 18 (11)
DOI: 10.4240/wjgs.124292 ↗Abstract
BACKGROUND Persistent Helicobacter pylori (H. pylori ) infection is associated with adverse outcomes after gastrectomy for gastric cancer. AIM To evaluate the association of perioperative H. pylori eradication therapy with longterm survival in patients undergoing distal gastrectomy for gastric cancer. METHODS This retrospective cohort study involved H. pylori -positive patients who underwent distal gastrectomy with D2 lymphadenectomy for gastric adenocarcinoma at our hospital from January 2016 to January 2021. The patients were divided into a perioperative eradication group and a non-eradication group depending on whether they received a 14-day bismuth-containing quadruple regimen. Key measurements included H. pylori status at 6 months, nutritional/inflammatory parameters at 12 months, remnant gastric lesions at 1 year, adjuvant chemotherapy completion, and long-term oncologic outcomes, including 5-year overall survival (OS) and disease-free survival (DFS). RESULTS Among the 271 eligible patients (143 non-eradication and 128 eradication), the eradication success rate was 91.41% in the eradication group. Compared with the non-eradication group, the eradication group was associated with significantly higher 5-year OS (91.41% vs 80.42%, P = 0.010) and 5-year DFS (85.94% vs 72.73%, P = 0.008) and lower rates of metachronous gastric cancer (1.56% vs 7.69%, P = 0.018) and gastric cancer-specific death (6.25% vs 15.38%, P = 0.017). Multivariate Cox regression analysis adjusting for age, sex, pathological tumor-node-metastasis stage, differentiation, and lymphovascular invasion revealed that perioperative eradication remained independently associated with improved OS (hazard ratio = 0.551, P = 0.036) and DFS (hazard ratio = 0.604, P = 0.043). CONCLUSION In this retrospective cohort, perioperative H. pylori eradication therapy was independently associated with improved long-term survival and reduced risk of metachronous gastric cancer in patients who underwent distal gastrectomy for gastric cancer.
EUVIMED